

10/589394  
IAP11 Rec'd PCT/PTO 15 AUG 2006

PATENT  
Customer No. 22,852  
Attorney Docket No. 01975.0099

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
	)	
Josephus H.M. LANGE et al.	)	Group Art Unit: Not Yet Assigned
	)	
Application No.: Not Yet Assigned	)	Examiner: Not Yet Assigned
	)	
§371 Application of PCT/EP/2005/050680	)	
	)	
For: IMIDAZOLINE DERIVATIVES	)	Confirmation No.: Not Yet Assigned
HAVING CB <sub>1</sub> -ANTAGONISTIC	)	
ACTIVITY	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants brings to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed concurrently with the above-identified application.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law,

10/589394

Customer No. 22,852

Attorney Docket No. 01975.0099-00

IAP11 Rec'd PCT/PTO 15 AUG 2006

Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: August 15, 2006

By: Michele C. Bosch  
Michele C. Bosch  
Reg. No. 40,524

10/589394

IAP11 Rec'd PCT/PTO 15 AUG 2006

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	To Be Assigned (\$371 Application of PCT/EP/2005/050680)
				Filing Date	August 15, 2006
				First Named Inventor	Josephus H.M. LANGE et al.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned.
Sheet	1	of	1	Attorney Docket Number	01975.0099-00

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1	US-5,952,535	09/14/1999	King et al.	
	2	US-6,960,601	11/01/2005	Smith et al.	
	3	US-2004/0122074	06/24/2004	Dow et al.	
	4	US-2004/0235854	11/25/2004	Kruse et al.	
	5	US-2005/0187259	08/25/2005	Lange et al. *see below	

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	5	WO 03/026647	4/03/2000	Solvay Pharmaceuticals B.V.		
	6	WO 03/027076	4/03/2003	Solvay Pharmaceuticals B.V.		
	7	WO 03/078413	09/25/2003	Solvay Pharmaceuticals B.V.		
	8	WO 03/101969	12/11/2003	Michigan State University		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
	9	International Preliminary Report on Patentability for International Application No. PCT/EP/2005/050680 (International Publication No. WO 2005/080345), Examiner I. Scruton-Evans, November 16, 2005.	
	10	International Search Report for International Application No. PCT/EP2005/050680.	
	11	Dyck et al., "Potent Imidazole and Triazole CB1 receptor Antagonists Related to SR141716," Bioorganic & Medicinal Chemistry Letters, Vol. 14, Iss. 5, pp. 1151-1154 (2004)	
	12	Khanna et al., "Selective Cyclooxygenase-2 Inhibitors: Heteroaryl Modified 1,2-Diarylimidazoles Are Potent, Orally Active Anti-inflammatory Agents," J. Med. Chem., vol. 43, 3168-3185 (2000).	
	13	Lange et al., "Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpirazolines as Potent and Elective CB <sub>1</sub> Cannabinoid Receptor Antagonists," J. Med. Chem., Vol. 47(3), pp. 627-643 (2004).	
	14	Co-pending U.S. Patent Application No. 11/058,168, Attorney Docket No. 01975.0067-00) to Henri SAMAIN et al., filed June 16, 2004 (* published as US-2005-0187259, on 8/25/2005	
	15	Co-pending U.S. Patent Application No. 11/058,168 (Attorney Docket No. 01975-0067-00), to Henri SAMAIN et al., filed June 16, 2004, Office Action, mailed 05/09/2006, Examiner A. Freistein	
Examiner Signature		Date Considered	